

## New CPT (Current Procedural Terminology) codes allow for potential reimbursement in USA

- HeraMED to pursue verification regarding potential reimbursement for its HeraCARE pregnancy management platform under the US reimbursement code system
- Follows FDA clearance for HeraMED's medical grade foetal heart rate monitor "HeraBEAT US"
- Company will continue to work closely and develop its solutions with its in-country medical advisors and partners to verify compatibility with the reimbursement process

Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") provides by way of this announcement for all investors, a response to a common question posed to the Company with regards to CPT reimbursement codes in the USA and how will they potentially benefit HeraMED.

Current Procedural Terminology (CPT) codes are a procedural code set used for reporting medical, diagnostic, and surgical services performed by healthcare providers. The copyright to CPT codes is held by the American Medical Association and the CPT codes are used nationwide.

Recently, six new CPT codes were introduced that help physicians and other healthcare professionals report a range of digital health services including in home monitoring and electronic patient visits. HeraMED plans to pursue verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed through these recently introduced CPT codes.

"With the advance of new technologies for e-visits and health monitoring, many patients are realizing the best access point for physician care is once again their home," AMA President Patrice A. Harris, MD, MA, said in a recent press release.

As part of its US market entry, HeraMED will engage with medical professionals and other expert consultants to verify if its HeraBEAT and HeraCARE platform may be eligible for reimbursement through the current set of CPT codes. The Company will also monitor for the introduction of new codes, which are expected over the course of 2020. If HeraMED's solutions are eligible, this may potentially drive uptake with key medical organisations and insurance companies throughout the country.

HeraMED will initially target the following codes, which if its solution use is accepted, will potentially result in a total of US\$115 in reimbursement per month, or a **full refund to the end user**. The CPT code allocation is determined by a dedicated CPT committee and insurance companies and while HeraMED is confident of a positive outcome, timing and path to allocation will be in the hands of third party providers.

- **CPT code 99453 - US\$19.46** on a one-off basis for the set up and patient education of solutions.
- **CPT code 99454 - US\$64.15** on a monthly basis for use of remote monitoring services including supply of daily recording and alert transmission.
- **CPT code 99547 - US\$51.54** (non-facility) and **US\$32.44** (facility) on a monthly basis for remote treatment monitoring services for 20 minutes or more by a clinical professional or healthcare professional requiring interactive communication with a patient or caregiver.

This development follows the Company receiving clearance from the US Food and Drug Administration (FDA) for its HeraBEAT device (refer ASX announcement: 18 November 2019). Board and management will provide further guidance on HeraMED's US market entry progresses across calendar year 2020.

For personal use only

**CEO and Co-founder Mr David Groberman said:** “These new codes represent the continued trend towards remote patient monitoring and will become imperative as hospitals and health systems look to extend their reach of care to the home and non-traditional settings.

“As healthcare providers look to further increase their collaborations with patients and other care providers, HeraMED becomes better positioned as an innovative technology provider and a potential early mover in digital pregnancy monitoring.

“The Company will continue to leverage its partnerships in the USA to progress its market entry and drive solution uptake.”

This announcement has been authorised by the Board of HeraMED Limited.

**-ENDS-**

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0) 8 6189 1155

E: stephen@companysecsol.com.au

**Released through:** Henry Jordan, Six Degrees Investor Relations, +61 431 271 538

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical Data and Technology company leading the digital transformation of prenatal care. HeraMED utilises the digital health ecosystem including clinical home monitoring devices, cloud computing, artificial intelligence, big data and digital social networking to reshape the Doctor/Patient relationship. The Company is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, to deliver better care at a lower cost. Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.